Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 478

1.

Adolescent talus body fracture with high displacement: A case report.

Hama S, Onishi R, Yasuda M, Minato K, Miyashita M.

Medicine (Baltimore). 2018 Aug;97(35):e12043. doi: 10.1097/MD.0000000000012043.

2.

Clinical Impact of Post-Progression Survival on Overall Survival in Elderly Patients with Non-Small-Cell Lung Cancer Harboring Sensitive EGFR Mutations Treated with First-Line EGFR Tyrosine Kinase Inhibitors.

Imai H, Yamada Y, Sugiyama T, Minemura H, Kaira K, Kanazawa K, Kasai T, Kaburagi T, Minato K; Gunma-Ibaraki-Fukushima-Tochigi (GIFT) group.

Chemotherapy. 2018;63(3):181-189. doi: 10.1159/000490949. Epub 2018 Aug 14.

PMID:
30107372
3.

Characteristics and outcomes of patients with EGFR-mutation positive non-small-cell lung cancer receiving gefitinib beyond radiological progression.

Hosomi Y, Tanai C, Yoh K, Goto Y, Sakai H, Kato T, Kaburagi T, Nishio M, Kim YH, Inoue A, Hasegawa Y, Isobe H, Tomizawa Y, Mori Y, Minato K, Yamada K, Ohashi Y, Kunitoh H.

Expert Opin Pharmacother. 2018 Jul;19(10):1049-1056. doi: 10.1080/14656566.2018.1484903. Epub 2018 Jun 21.

PMID:
29871540
4.

Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations.

Imai H, Minemura H, Sugiyama T, Yamada Y, Kaira K, Kanazawa K, Kasai T, Kaburagi T, Minato K; Gunma-Ibaraki-Fukushima-Tochigi (GIFT) Group.

Cancer Chemother Pharmacol. 2018 Jul;82(1):119-127. doi: 10.1007/s00280-018-3596-6. Epub 2018 May 8.

PMID:
29737372
5.

Dietary patterns and prostate cancer risk in Japanese: the Japan Public Health Center-based Prospective Study (JPHC Study).

Shin S, Saito E, Sawada N, Ishihara J, Takachi R, Nanri A, Shimazu T, Yamaji T, Iwasaki M, Sasazuki S, Inoue M, Tsugane S; JPHC Study Group.

Cancer Causes Control. 2018 Jun;29(6):589-600. doi: 10.1007/s10552-018-1030-3. Epub 2018 Apr 18.

PMID:
29671180
6.

Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations.

Oizumi S, Sugawara S, Minato K, Harada T, Inoue A, Fujita Y, Maemondo M, Watanabe S, Ito K, Gemma A, Demura Y, Fukumoto S, Isobe H, Kinoshita I, Morita S, Kobayashi K, Hagiwara K, Aiba K, Nukiwa T.

ESMO Open. 2018 Feb 23;3(2):e000313. doi: 10.1136/esmoopen-2017-000313. eCollection 2018.

7.

Overall Survival Results of the Feasibility Study of Adjuvant Chemotherapy With Docetaxel Plus Cisplatin Followed by Long-term Single-agent Administration of S-1 in Patients With Completely Resected Non-Small Cell Lung Cancer: Thoracic Oncology Research Group (TORG) 0809.

Niho S, Ikeda N, Michimae H, Suzuki K, Sakai H, Kaburagi T, Yoshiya K, Minato K, Kato T, Okamoto H, Seto T, Hosomi Y, Shimizu K, Saito H, Tsuchida M, Kunitoh H, Tsuboi M, Takeuchi M, Watanabe K.

Am J Clin Oncol. 2018 Mar 7. doi: 10.1097/COC.0000000000000438. [Epub ahead of print]

PMID:
29521649
8.

The effect of post-progression survival on overall survival among patients with sensitive relapse of small cell lung cancer.

Miura Y, Imai H, Sakurai R, Kaira K, Sunaga N, Minato K, Saito R, Hisada T.

Med Oncol. 2018 Mar 5;35(4):45. doi: 10.1007/s12032-018-1107-6.

PMID:
29508094
9.

Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).

Tahara M, Kiyota N, Yokota T, Hasegawa Y, Muro K, Takahashi S, Onoe T, Homma A, Taguchi J, Suzuki M, Minato K, Yane K, Ueda S, Hara H, Saijo K, Yamanaka T.

Ann Oncol. 2018 Apr 1;29(4):1004-1009. doi: 10.1093/annonc/mdy040.

PMID:
29408977
10.

A Phase I Study of Hypofractionated Carbon-ion Radiotherapy for Stage III Non-small Cell Lung Cancer.

Saitoh JI, Shirai K, Abe T, Kubo N, Ebara T, Ohno T, Minato K, Saito R, Yamada M, Nakano T; WORKING GROUP OF THE LUNG TUMOR.

Anticancer Res. 2018 Feb;38(2):885-891.

PMID:
29374716
11.

Plasma levels of n-3 fatty acids and risk of coronary heart disease among Japanese: The Japan Public Health Center-based (JPHC) study.

Hamazaki K, Iso H, Eshak ES, Ikehara S, Ikeda A, Iwasaki M, Hamazaki T, Tsugane S; JPHC Study Group.

Atherosclerosis. 2018 May;272:226-232. doi: 10.1016/j.atherosclerosis.2017.12.004. Epub 2017 Dec 8.

PMID:
29277442
12.

Bone Resection for Isolated Ulnar Head Fracture.

Akino H, Hama S, Yasuda M, Minato K, Miyashita M.

Case Rep Orthop. 2017;2017:3519146. doi: 10.1155/2017/3519146. Epub 2017 Oct 26.

13.

Real-world practice patterns for patients with advanced non-small cell lung cancer: multicenter retrospective cohort study in Japan.

Isobe H, Mori K, Minato K, Katsura H, Taniguchi K, Arunachalam A, Kothari S, Cao X, Kato T.

Lung Cancer (Auckl). 2017 Oct 24;8:191-206. doi: 10.2147/LCTT.S140491. eCollection 2017.

14.

A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy.

Yanai T, Iwasa S, Hashimoto H, Ohyanagi F, Takiguchi T, Takeda K, Nakao M, Sakai H, Nakayama T, Minato K, Arai T, Suzuki K, Shimada Y, Nagashima K, Terakado H, Yamamoto N.

Int J Clin Oncol. 2018 Apr;23(2):382-388. doi: 10.1007/s10147-017-1200-4. Epub 2017 Oct 16.

PMID:
29039073
15.

Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study.

Goto Y, Tanai C, Yoh K, Hosomi Y, Sakai H, Kato T, Kaburagi T, Nishio M, Kim YH, Inoue A, Hasegawa Y, Isobe H, Tomizawa Y, Mori Y, Minato K, Yamada K, Ohashi Y, Kunitoh H.

ESMO Open. 2017 Sep 14;2(4):e000214. doi: 10.1136/esmoopen-2017-000214. eCollection 2017.

16.

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M; PACIFIC Investigators.

N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8.

17.

Alcohol consumption and bladder cancer risk with or without the flushing response: The Japan Public Health Center-based Prospective Study.

Masaoka H, Matsuo K, Sawada N, Yamaji T, Goto A, Shimazu T, Iwasaki M, Inoue M, Eto M, Tsugane S; Japan Public Health Center-based Prospective Study Group.

Int J Cancer. 2017 Dec 15;141(12):2480-2488. doi: 10.1002/ijc.31028. Epub 2017 Sep 15.

PMID:
28875523
18.

Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer.

Nishio M, Hida T, Atagi S, Sakai H, Nakagawa K, Takahashi T, Nogami N, Saka H, Takenoyama M, Maemondo M, Ohe Y, Nokihara H, Hirashima T, Tanaka H, Fujita S, Takeda K, Goto K, Satouchi M, Isobe H, Minato K, Sumiyoshi N, Tamura T.

ESMO Open. 2017 Mar 7;1(4):e000108. doi: 10.1136/esmoopen-2016-000108. eCollection 2016.

19.

Dietary magnesium intake and risk of incident coronary heart disease in men: A prospective cohort study.

Kokubo Y, Saito I, Iso H, Yamagishi K, Yatsuya H, Ishihara J, Maruyama K, Inoue M, Sawada N, Tsugane S; JPHC Study Group.

Clin Nutr. 2017 Aug 12. pii: S0261-5614(17)30274-1. doi: 10.1016/j.clnu.2017.08.006. [Epub ahead of print]

PMID:
28843443
20.

Prognostic effect of class III β-tubulin and Topoisomerase-II in patients with advanced thymic carcinoma who received combination chemotherapy, including taxanes or topoisomerase-II inhibitors.

Miura Y, Kaira K, Sakurai R, Imai H, Tomizawa Y, Sunaga N, Minato K, Hisada T, Oyama T, Yamada M.

Oncol Lett. 2017 Aug;14(2):2369-2378. doi: 10.3892/ol.2017.6419. Epub 2017 Jun 19.

Supplemental Content

Loading ...
Support Center